Understanding the benefits and challenges of first-line cyclin-dependent kinases 4 and 6 inhibitors in advanced breast cancer among postmenopausal women.

Azim, Hamdy A; Dawood, Shaheenah; El-Saghir, Nagi; Kassem, Loay; Azim, Hatem A

Azim, Hamdy A; Dawood, Shaheenah; El-Saghir, Nagi; Kassem, Loay; Azim, Hatem A.

Afiliación

Azim HA; Department of Clinical Oncology, Faculty of Medicine, Cairo University, Cairo, Egypt.
Dawood S; Cairo Oncology Centre, Cairo, Egypt.
El-Saghir N; Department of Medical Oncology, Mediclinic City Hospital, Comprehensive Cancer Center, Dubai Health Care City, Dubai, UAE.
Kassem L; American University of Beirut Medical Center, Beirut, Lebanon.
Azim HA; Department of Clinical Oncology, Faculty of Medicine, Cairo University, Cairo, Egypt.

Breast J ; 26(4): 630-642, 2020 04.

Article en En | MEDLINE | ID: mdl-31709685

Asunto(s)

Neoplasias de la Mama; Neoplasias de la Mama/tratamiento farmacológico; Quinasa 4 Dependiente de la Ciclina; Femenino; Humanos; Terapia Molecular Dirigida; Posmenopausia; Inhibidores de Proteínas Quinasas/uso terapéutico

Palabras clave

CDK inhibitors; HER2-negative; advanced breast cancer; estrogen receptor-positive; first-line endocrine therapy; review

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Límite: Female / Humans Idioma: En Revista: Breast J Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Egipto

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google